Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In-vitro model to mimic T cell subset change in human PDAC organoid co-culture.
Knoblauch M, Ma T, Beirith I, Koch D, Hofmann F, Heinrich K, Aghamaliev U, Sirtl S, Westphalen CB, Nieß H, Reichert M, Angele MK, Regel I, Bazhin AV, Werner J, Ilmer M, Renz BW. Knoblauch M, et al. Among authors: heinrich k. J Cancer Res Clin Oncol. 2023 Nov;149(14):13051-13064. doi: 10.1007/s00432-023-05100-7. Epub 2023 Jul 20. J Cancer Res Clin Oncol. 2023. PMID: 37470855 Free PMC article.
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L, Heinrich K, Zhang D, Dorman K, Rühlmann K, Hasselmann K, Klauschen F, Kumbrink J, Jung A, Rudelius M, Mock A, Ormanns S, Kunz WG, Roessler D, Beyer G, Corradini S, Heinzerling L, Haas M, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Weiss L, et al. Among authors: heinrich k. J Cancer Res Clin Oncol. 2023 Sep;149(11):8225-8234. doi: 10.1007/s00432-023-04741-y. Epub 2023 Apr 16. J Cancer Res Clin Oncol. 2023. PMID: 37062035 Free PMC article.
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
Boukovala M, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Heinrich K, Neumann J, Jung A, Held S, Stintzing S, Heinemann V, Michl M. Boukovala M, et al. Among authors: heinrich k. ESMO Open. 2024 May;9(5):103374. doi: 10.1016/j.esmoop.2024.103374. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744100 Free PMC article. Clinical Trial.
Tirzepatide and exercise training in obesity.
Bagherzadeh-Rahmani B, Marzetti E, Karami E, Campbell BI, Fakourian A, Haghighi AH, Mousavi SH, Heinrich KM, Brazzi L, Jung F, Baker JS, Patel DI. Bagherzadeh-Rahmani B, et al. Among authors: heinrich km. Clin Hemorheol Microcirc. 2024 Apr 12. doi: 10.3233/CH-242134. Online ahead of print. Clin Hemorheol Microcirc. 2024. PMID: 38640145
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors.
Ingenerf M, Auernhammer C, Lorbeer R, Winkelmann M, Mansournia S, Mansour N, Hesse N, Heinrich K, Ricke J, Berger F, Schmid-Tannwald C. Ingenerf M, et al. Among authors: heinrich k. Radiol Oncol. 2024 Apr 14. doi: 10.2478/raon-2024-0024. Online ahead of print. Radiol Oncol. 2024. PMID: 38613843 Free article.
485 results